Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509971 | 1.00 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL3720132 | 0.93 | CNR1 (0.79) | CNR1CNR2 | |
| SCHEMBL3479325 | 0.92 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL29510144 | 0.92 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3718089 | 0.90 | CNR1 (0.83) | CNR1CNR2 | |
| SCHEMBL14043696 | 0.90 | CNR1 (0.83) | CNR1CNR2 | |
| SCHEMBL3479324 | 0.88 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3719511 | 0.87 | CNR1 (0.88) | CNR1CNR2 | |
| SCHEMBL3479375 | 0.85 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL14043698 | 0.85 | CNR1 (0.75) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | claimed |
| EP-2139333-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008118414-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | SPOKE SCIENCES, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | SPOKE SCIENCES, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| US-20240261303-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | SPOKE SCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20240009208-A1 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | RECEPTOR HOLDINGS, INC. (US) | 2024-01-11 | — | — | US | disclosed |
| WO-2023201303-A2 | SYSTEMS AND METHODS TO AUTOMATICALLY ADMINISTER A PSYCHOACTIVE SUBSTANCE TO AN AIRWAY OF A USER BASED ON A DETECTED EVENT OR CONDITION | Green Sky Creations, LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230293479-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20200254041-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | RECEPTOR HOLDINGS, INC. (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3672610-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | Receptor Holdings, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3565539-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | Receptor Holdings, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20190336472-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2019-11-07 | — | — | US | disclosed |
| WO-2019071213-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | RECEPTOR LIFE SCIENCES, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| WO-2018129097-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR LIFE SCIENCES (US) | 2018-07-12 | — | — | WO | disclosed |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| WO-2008118414-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293479-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | GPR18, SLC1A5, CNR2 | CNR1 4/4885CNR2 3/4885 |
| US-20100029697-A1 | SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885 |
| US-20250152509-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND LIQUID COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | NAPEPLD, CNR1, CNR2 | CNR1 2/4885CNR2 3/4885 |
| US-20250268861-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | CNR1 5/4885CNR2 2/4885 |
| US-20200254041-A1 | RAPID ONSET AND EXTENDED ACTION PLANT-BASED AND SYNTHETIC CANNABINOID FORMULATIONS | FAAH, CNR1, GPR18 | CNR1 2/4885CNR2 4/4885 |
| US-12303487-B2 | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions | FAAH, CNR2, FABP2 | CNR1 5/4885CNR2 2/4885 |
| US-20190336472-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | GPR18, SLC1A5, CNR2 | CNR1 4/4885CNR2 3/4885 |
| US-20240009208-A1 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | DGKZ, DSP, DMPK | CNR1 17/4885CNR2 6/4885 |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | CNR1 2/4885CNR2 1/4885 |
| US-20240261303-A1 | PARTICLES, AQUEOUS DISPERSIONS, AND COMPOSITIONS HAVING HIGH LIPOPHILIC COMPONENT CONCENTRATIONS AND HIGH LIPOPHILIC COMPONENT TO SURFACTANT RATIOS | LIPA, PLIN3, LPL | CNR1 835/4885CNR2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.